Maxim Group Begins Coverage on BioHarvest Sciences (NASDAQ:BHST)

Stock analysts at Maxim Group initiated coverage on shares of BioHarvest Sciences (NASDAQ:BHST) in a research report issued on Wednesday, MarketBeat reports. The brokerage set a “buy” rating and a $12.00 price target on the stock. Maxim Group’s target price points to a potential upside of 93.55% from the company’s current price.

Separately, HC Wainwright initiated coverage on BioHarvest Sciences in a research note on Friday, December 6th. They set a “buy” rating and a $14.00 target price on the stock.

BioHarvest Sciences Price Performance

NASDAQ:BHST opened at $6.20 on Wednesday. BioHarvest Sciences has a 52 week low of $6.09 and a 52 week high of $7.70. The stock has a market capitalization of $101.84 million and a price-to-earnings ratio of -4.96.

BioHarvest Sciences Company Profile

BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.